| The pharmaceutical industry is becoming increasingly aware of the value of understanding the patient beyond just their symptoms and drug journey. Emotions, socioeconomics, symptoms, family dynamic, knowledge and sentiment are all part of the 360° understanding of the patient. These patient details can be blockers for participation in clinical trials, impactors on successful outcomes, impact diversity in trials. ICON’s director of social intelligence & communities will discuss how social listening can uncover the unsolicited and unfiltered voice of the patient that should be a key component in trial participation considerations as well as sentiment around treatments, adverse events, and symptom trends. |
